- Trial Phase
- Phase 3
- Time to Market
- If the OCEAN(a)-Outcomes readout around December 2026 is positive, Amgen would likely submit a New Drug Application to the FDA in 2027, with potential approval in 2028 or later, assuming the trial demonstrates cardiovascular event reduction.
- Why 7/10
- The next hard, dated catalyst is the topline readout of the Phase 3 OCEAN(a)-Outcomes trial, expected around December 2026 (within approximately one month). This is a pivotal cardiovascular outcomes readout for a major pipeline asset at Amgen, a diversified large-cap biotech with many approved products. The score of 7 reflects a dated binary catalyst within ~6 months on an asset that is a major value driver at a company that also has other substantial programs.
The OCEAN(a)-Outcomes topline readout expected around December 2026 is the single most important near-term catalyst for olpasiran. A positive result showing cardiovascular event reduction would validate the Lp(a) hypothesis after Novartis' pelacarsen failure and could unlock a multi-billion-dollar market, while a negative result would likely cast doubt on the entire drug class and weigh on Amgen shares. The stock's recent recovery to near 52-week highs and broad analyst price-target increases suggest some optimism, but the class-wide skepticism from the pelacarsen miss means the bar for proof is high.
Price Chart
Executive Summary
Olpasiran (AMG 890) is Amgen's investigational siRNA therapy designed to lower Lipoprotein(a), a genetically inherited risk factor for heart disease. Phase 2 data showed it reduces Lp(a) by up to ~97% with once-quarterly injections. The pivotal Phase 3 OCEAN(a)-Outcomes trial in about 7,300 patients is expected to report topline results around December 2026, testing whether Lp(a) reduction actually prevents heart attacks and strokes. This readout comes after Novartis' competing drug pelacarsen failed its Phase 3 outcomes trial in September 2026, which sent Amgen shares down ~10% on class-wide skepticism. Olpasiran's greater Lp(a) reduction and different siRNA mechanism offer potential differentiation, but the class now faces a higher evidentiary bar. Amgen is a large, diversified biotech, so olpasiran is one of several value drivers rather than a make-or-break asset.
How It Works
Olpasiran is a small interfering RNA (siRNA) drug that silences the gene responsible for producing Lipoprotein(a), or Lp(a), a fatty particle in the blood that is a genetically determined risk factor for heart attacks and strokes. It is injected under the skin once every 12 weeks and works inside liver cells to stop Lp(a) production at its source.
Trial Status
The pivotal Phase 3 OCEAN(a)-Outcomes trial (NCT05581303) enrolled about 7,300 patients with established atherosclerotic cardiovascular disease and elevated Lp(a). It started in December 2022 and is active but no longer recruiting. The trial tests whether olpasiran reduces the risk of coronary heart disease death, heart attack, or urgent coronary revascularization versus placebo. ClinicalTrials.gov lists primary completion as March 2028, but Amgen has guided to a topline readout around December 2026. A second Phase 3 trial, OCEAN(a)-PreEvent (NCT07136012), is testing olpasiran as a primary prevention in about 11,000 patients and started in August 2025. The Phase 2 OCEAN(a)-DOSE study completed and showed Lp(a) reductions of up to approximately 97%.
The Two-Sided Case
Upcoming Catalysts
- Topline readout of Phase 3 OCEAN(a)-Outcomes trial expected around December 2026 (within approximately one month)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Amgen PRESS-RELEASE AMGN ·Originating report